Concomitant endothelin-1 overexpression in lung transplant donors and recipients predicts primary graft dysfunction

Am J Transplant. 2010 Mar;10(3):628-36. doi: 10.1111/j.1600-6143.2009.02957.x. Epub 2010 Jan 5.

Abstract

Primary graft dysfunction (PGD) causes significant morbidity following lung transplantation (LTX). Mortality is high in PGD and therapeutic strategies are limited. To investigate whether endothelin-1 (ET-1) that mediates increased vascular permeability and edema formation in lung grafts can predict PGD, ET-1 mRNA expression was examined in lung tissue biopsies of 105 donors and recipients obtained shortly before LTX. Serum ET-1 concentration was assessed by ELISA. PGD grade was diagnosed and scored by oxygenation and radiological characteristics according to ISHLT guidelines. PGD grade 3 developed in 11% of patients. ET-1 mRNA expression was significantly increased in both donor (p < 0.0001) and recipient (p = 0.01) developing PGD as compared to no PGD group. Pretransplant ET-1 serum concentrations were elevated in recipients with PGD as compared to no PGD group (p < 0.0001), although serum ET-1 was not different between donors whose grafts developed PGD grades 0-3. In regression analysis, concomitant elevated donor tissue ET-1 and recipient serum ET-1 predicted PGD grade 3. This study indicates that pretransplant ET-1 mRNA overexpression in donors associated with elevated pretransplant serum ET-1 in recipients contribute to PGD development and that their assessment might be beneficial to predict PGD and to identify recipients who could benefit from a targeted ET-1 blockade.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Endothelin-1 / metabolism*
  • Enzyme-Linked Immunosorbent Assay / methods
  • Female
  • Humans
  • Lung Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Primary Graft Dysfunction / etiology*
  • Prospective Studies
  • RNA, Messenger / metabolism
  • Regression Analysis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tissue Donors
  • Treatment Outcome

Substances

  • Endothelin-1
  • RNA, Messenger